CJC-1295 (No DAC)

Mod GRF 1-29. Short-acting GHRH analogue for pulsatile GH release. The ideal partner for Ipamorelin.

Last updated: May 2026

What is CJC-1295 (No DAC)?

CJC-1295 without DAC (also known as Modified GRF 1-29 or Mod GRF 1-29) is a truncated, stabilized form of GHRH (Growth Hormone Releasing Hormone) with a half-life of approximately 30 minutes. Unlike CJC-1295 with DAC, it does not bind to albumin and is cleared relatively quickly from the body. Browse the full peptide library for related GH compounds.

This shorter half-life means it produces a sharp, pulsatile GH release that more closely mimics the natural pattern of GH secretion, a burst every few hours. When combined with Ipamorelin (which activates the GH secretagogue receptor), the two peptides work synergistically to produce significantly higher and more sustained GH pulses than either can achieve alone.

CJC-1295 (no DAC) + Ipamorelin is considered the gold-standard GH protocol in the peptide community. It's favored for its physiological GH pattern, excellent tolerability, and the ability to time doses strategically (pre-sleep, pre-workout). For FDA-approved visceral fat reduction specifically, see tesamorelin.

How It Works

GHRH Mimicry: Binds to GHRH receptors in the pituitary, signaling it to release stored GH. Acts like a "command" signal.

Short Half-Life Advantage: The ~30 minute half-life means each dose creates a clean GH pulse that rises and falls naturally, mimicking physiological GH patterns rather than creating a sustained bleed.

Ipamorelin Synergy: While CJC (no DAC) signals the pituitary to release GH, Ipamorelin amplifies that signal via the ghrelin receptor. Combined, GH output is substantially higher than either alone.

Benefits

Natural pulsatile GH release pattern
Excellent synergy with Ipamorelin (gold-standard stack)
Strategic timing possible (sleep, workout)
Less water retention vs CJC with DAC
Improved sleep, recovery, and body composition
Lower risk of pituitary desensitization vs DAC version

Dosing Described in Research and Labels

Phase	Dose	Frequency	Duration
GH secretagogue (research)	No established human dose	Subcutaneous (research)	Not established

These figures summarise what published research and approved labels describe. They are educational, not a recommendation or a personal protocol. Any dose, schedule, or decision to use a compound belongs with a licensed prescriber.

Side Effects

Common

⚠Mild water retention (less than DAC version)
⚠Tingling in hands/feet
⚠Mild hunger increase
⚠Headache in first week

Rare

•Hypoglycemia
•Pituitary desensitization with very high doses

Who Should NOT Use CJC-1295 (No DAC)

✕Active cancer
✕Diabetic retinopathy
✕Pregnancy or breastfeeding

What to Expect

Week 1 to 2

Improved sleep quality is often the first sign. Mild water retention possible.

Week 3 to 6

Faster recovery. Better body composition. Skin quality improving.

Month 2 to 3

Clear anabolic and fat-loss effects when combined with training and diet.

Month 3+

Complete the cycle and take a 4 week break before repeating.

Notes from Ho Chi Minh City

The CJC no-DAC plus Ipamorelin pairing is the GH-secretagogue stack the HCMC scene treats as a year-round staple, run in cycles rather than continuously. The rationale the research supports is that the GH pulse during slow-wave sleep is where most of the recovery and skin-quality benefit sits, which is why the pairing is timed around sleep and a fasted window. The no-DAC version is generally preferred over the DAC form here because it gives a cleaner pulse without the water retention that DAC plus HCMC heat produces. Handling matters: reconstituted peptide needs bacteriostatic water from a verified supplier and refrigeration, since sterile water alone leaves too short a shelf life to be practical. Dose, timing, and stack design are decisions for a licensed prescriber, not a fixed forum protocol.

FAQ

Q: Do I need to use CJC (no DAC) and Ipamorelin together?

A: You can use either alone, but the combination is significantly more effective. They work through different receptors (GHRH vs ghrelin) and the synergy produces substantially higher GH output. The stack is widely considered the minimum effective approach.

Q: How many times per day should I dose?

A: Frequency follows from the short half-life rather than a set rule: because the no-DAC form clears quickly, the variables people discuss are timing relative to sleep and whether to add a daytime dose, and a fasted state is where the research describes GH release as least blunted by insulin. How many doses, and when, are decisions for a licensed prescriber, not a forum default. Source from the community-verified supplier list.

Where to Get CJC-1295 (No DAC) in Vietnam

See our community-verified supplier list with COA verification and cold-chain shipping to Vietnam.

View Supply Index

Related Peptides

Ipamorelin CJC-1295 (with DAC)Tesamorelin MOTS-c

Research & Sources

Effects of an analog of growth hormone-releasing factor on GH secretion in normal human subjects · Jette L, Leger R, Thibaudeau K, et al. · Endocrinology (2005) PMID: 15919742
Pharmacokinetic and pharmacodynamic data underlying the short half-life advantage of Mod GRF 1-29.
Synergy between GHRH and a GH-releasing peptide for stimulation of GH release in humans · Bowers CY, Granda R, Mohan S, Kuipers J, Baylink D, Veldhuis JD · Journal of Clinical Endocrinology and Metabolism (2004) PMID: 15292313
Demonstrates the synergistic GH release when GHRH analogues are combined with GH secretagogues like ipamorelin.
Pulsatile growth hormone secretion in normal man · Hartman ML, Veldhuis JD, Thorner MO · Hormone Research (1993) PMID: 8330775
Defines the natural pulsatile GH pattern that the CJC no-DAC plus ipamorelin protocol attempts to replicate.
Long-acting albumin-binding GHRH analogues: insights into the design of CJC-1295 · Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA · Journal of Clinical Endocrinology and Metabolism (2006) PMID: 16380436
Compares DAC vs non-DAC CJC-1295 forms to clarify the trade-off between sustained vs pulsatile GH release.

Important Disclaimer

Educational content only. Not medical advice. Peptides discussed on this page are not approved by Vietnam’s Ministry of Health (Bộ Y Tế) or the Drug Administration of Vietnam (DAV) for the indications described. Research peptides are not stocked at Long Châu, Pharmacity, or any retail pharmacy in Vietnam. Consult a licensed physician before any use.